Category

Research Review
Issue 24 of Multiple Myeloma Research Review.   Highlights include: Is MRD the best predictor of response? ctDNA and risk of distant relapse. Cardiac safety of bortezomib. Cytogenic evolution in relapsed MM. Download here
Continue Reading
Issue 23 of Multiple Myeloma Research Review.   Highlights include: • Revised Myeloma Comorbidity index for multiple myeloma prognosis. • Genetic basis for zoledronic-acid related osteonecrosis of the jaw. • Front-line carfilzomib-containing regimens for multiple myeloma. • Multiple myeloma prognoses predicted by immunoglobulin recovery post-SCT.   Download here
Continue Reading
This publication is a summary of selected presentations delivered at the Haematology Society of Australia and New Zealand (HSANZ) Inaugural International Myeloma Summit Meeting held in Queenstown in August 2016. The exciting program featured two international speakers, Professor Paul Richardson from the Dana-Farber Cancer Institute, Boston and Professor Ola Landgren from the Memorial Sloan-Kettering Cancer...
Continue Reading
Issue 22 of Multiple Myeloma Research Review. Highlights include: •   Benefits of low dose lenalidomide in relapsed/refractory MM. •   Network meta-analysis: treatment outcomes in relapsed/refractory MM. •   Improved outcomes for patients treated a speciality MM clinics. •   Real world benefits of bortezomib regimens for non-transplant eligible MM. Download here
Continue Reading
This latest report is a study published in the British Journal of Haematology comparing whole-body ultra-low dose CT (WBULDCT) with spinal MRI (SMRI) in the assessment of disease in multiple myeloma. ‘Diagnostic value of whole-body ultra-low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma’ focuses on...
Continue Reading
1 2

Floor 7, 90 The Terrace
Wellington Central
New Zealand